Business Context and Reporting Period
Company: Landec Corporation (filing as Landec Corporation; request metadata referenced Lifecore Biomedical, Inc., which was acquired by Landec on April 30, 2010).
Reporting Period: Fiscal year ended May 30, 2010.
Overview: Landec designs, develops, and sells polymer products for food, agriculture, and medical devices. Following the acquisition of Lifecore Biomedical, Inc. on April 30, 2010, the Company operates four core segments: Food Products Technology (Apio), Commodity Trading, Hyaluronan-based Biomaterials (Lifecore), and Technology Licensing. The Company is an accelerated filer with common stock traded on the NASDAQ Global Select Market under the symbol "LNDC."
Key Financial Metrics
| Metric | Fiscal 2010 | Fiscal 2009 |
|---|---|---|
| Total Revenues | $238.2 million | $235.9 million |
| Gross Profit | $33.8 million | $34.3 million |
| Operating Profit | $11.7 million | $12.6 million |
| Net Income (Applicable to Common Stockholders) | $4.0 million | $7.7 million |
| Diluted EPS | $0.15 | $0.29 |
| Cash and Cash Equivalents (End of Period) | $27.8 million | $43.5 million |
| Total Debt | $23.8 million | $0 |
| Capital Expenditures | $5.2 million | $4.6 million |
Segment Performance (Fiscal 2010):
- Food Products Technology: $175.0 million revenue; $22.5 million gross profit.
- Commodity Trading: $54.9 million revenue; $3.9 million gross profit.
- Hyaluronan-based Biomaterials: $1.5 million revenue (one month post-acquisition); $0.8 million gross profit.
- Technology Licensing: $6.8 million revenue; $6.5 million gross profit.
Material Changes vs. Prior Period
- Acquisition of Lifecore: The most significant change was the acquisition of Lifecore Biomedical, Inc. on April 30, 2010, for approximately $40 million in cash plus up to $10 million in earn-out payments. This added the Hyaluronan-based Biomaterials segment. The acquisition was funded by a new $20 million credit facility with Wells Fargo Bank.
- Revenue Growth: Total revenue increased 1% year-over-year, driven by a 4% increase in Food Products Technology value-added sales (due to a 14% volume increase) and the inclusion of Lifecore. This was partially offset by a 9% decline in Commodity Trading revenue due to produce shortages.
- Profitability Decline: Net income decreased 49% to $4.0 million. This was primarily due to $3.7 million in "Other Expenses," consisting of $2.7 million in acquisition-related transaction costs and a $1.0 million impairment charge on an investment in Aesthetic Sciences. Additionally, the effective tax rate increased to 51% from 42% in the prior year.
- Liquidity: Cash and cash equivalents decreased by $15.7 million to $27.8 million, primarily due to the $39.7 million net cash outflow for the Lifecore acquisition and $5.2 million in capital expenditures.
Guidance, Outlook, and Risks
Outlook and Capital Needs: Management anticipates capital expenditures of approximately $6.0 million to $6.5 million for fiscal 2011 to complete a 40,000 square foot expansion of the Apio processing plant and meet Lifecore's capital needs. The Company believes existing cash and operating cash flows will be sufficient for the next twelve months.
Key Risks and Contingencies:
- Integration Risk: Uncertainty regarding the successful integration of Lifecore's operations and realization of anticipated synergies.
- Customer Concentration: The top five customers accounted for 48% of total revenue, with Costco Wholesale Corporation representing approximately 20%.
- Regulatory Compliance: Significant exposure to FDA regulations for medical devices (Lifecore) and food safety regulations (Apio). Failure to obtain or maintain approvals could materially impact operations.
- Supply Chain: Dependence on single-source suppliers for certain raw materials and exposure to weather conditions affecting produce supply and pricing.
- Goodwill Impairment: The balance sheet includes significant goodwill ($41.2 million). Future impairment tests could result in write-offs if fair value declines.
Investor Verification Checklist
- Debt Covenants: Verify compliance with the new Wells Fargo credit agreement covenants (minimum net income, quick ratio, fixed coverage ratio), noting an amendment was made in August 2010 to adjust these terms.
- Lifecore Integration: Monitor the progress of integrating Lifecore's manufacturing and sales operations and the achievement of revenue targets for the $10 million earn-out.
- Customer Concentration: Assess the stability of the relationship with Costco (20% of revenue) and the impact of any potential order cancellations.
- Regulatory Status: Confirm the status of FDA approvals for Lifecore's new product developments and any ongoing audits of Apio's food safety protocols.
- Stock Repurchase Plan: Note the July 2010 approval of a $10 million stock repurchase plan and monitor execution.